B&K CORP-B(02396),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02396 B&K CORP-B

Not Yet Opened 08-12 14:43:00

3.800

+0.000

0.00%

High3.800	Low3.800	Vol10.40K
Open3.800	D1 Closing3.800	Amplitude0.00%
Mkt Cap447.10M	Tradable Cap315.48M	Total Shares117.66M
T/O39.52K	T/O Rate0.01%	Tradable Shares83.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02396","market":"HK","secType":"STK","nameCN":"B&K CORP-B","latestPrice":3.8,"timestamp":1786516980123,"preClose":3.8,"halted":0,"volume":10400,"delay":0,"changeRate":0,"floatShares":83022145,"shares":117657522,"eps":-2.419604494946325,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-12 14:43:00","open":3.8,"high":3.8,"low":3.8,"amount":39520,"amplitude":0,"askPrice":3.85,"askSize":9000,"bidPrice":3.8,"bidSize":7200,"shortable":0,"etf":0,"ttmEps":-2.2881548276727988,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786584600000},"marketStatusCode":0,"adr":0,"listingDate":1766332800000,"exchange":"SEHK","adjPreClose":3.8,"openAndCloseTimeList":[[1786498200000,1786507200000],[1786510800000,1786521600000]],"volumeRatio":0.682415,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02396","defaultTab":"news","newsList":[{"id":"1125385556","title":"B&K Corp Schedules 14 August 2026 Board Meeting to Approve 1H26 Results and Consider Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1125385556","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125385556?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:45","pubTimestamp":1785836730,"startTime":"0","endTime":"0","summary":"B&K Corporation Limited announced that its board of directors will meet on 14 August 2026 to review and approve the interim financial results for the six months ended 30 June 2026. The agenda also...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656531566","title":"B&K Corp Sets Board Meeting to Weigh Interim Results, Possible Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2656531566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656531566?lang=en_us&edition=fundamental","pubTime":"2026-08-04 17:41","pubTimestamp":1785836500,"startTime":"0","endTime":"0","summary":"B&K Corp sets board meeting to weigh interim results, possible dividendB&K Corporation will hold a board meeting on Aug. 14, 2026 to review interim results for the six months ended June 30, 2026.The b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLbX3nGR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131929217","title":"B&K Reports Stable Share Capital and Full Public Float Compliance in July 2026 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1131929217","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131929217?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:26","pubTimestamp":1785767194,"startTime":"0","endTime":"0","summary":"B&K Corporation Limited (B&K) has submitted its Monthly Return to Hong Kong Exchanges and Clearing Limited for the period ended 31 July 2026, confirming that its share capital structure and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192798385","title":"B&K Announces Chinese Name Change to 青城新藥生物科技(青島)股份有限公司; Chinese Stock Short Name Shifts to「青城新藥－B」on 22 July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1192798385","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192798385?lang=en_us&edition=fundamental","pubTime":"2026-07-17 17:02","pubTimestamp":1784278943,"startTime":"0","endTime":"0","summary":"B&K Corporation Limited has formally completed the change of its registered Chinese name from「華芢生物科技(青島)股份有限公司」to「青城新藥生物科技(青島)股份有限公司」, effective 13 July 2026. The English name “B&K Corporation...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110015801","title":"B&K CORP-B Announces Formal Name Change to Qingcheng New Drug Biotechnology","url":"https://stock-news.laohu8.com/highlight/detail?id=1110015801","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110015801?lang=en_us&edition=fundamental","pubTime":"2026-07-17 16:45","pubTimestamp":1784277942,"startTime":"0","endTime":"0","summary":"An announcement has been issued by B&K CORP-B (ASX: 02396) regarding a formal alteration to its corporate identity.The company's registered Chinese name has been officially changed from \"Huaren...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","159837","SYNB","BK1161","GDOC","XBI","02396","MEDX","BK4588","HBImain","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194702144","title":"B&K: Completes Full Enrollment for Phase II Trial of Diabetic Foot Ulcer Therapy Pro-101-2","url":"https://stock-news.laohu8.com/highlight/detail?id=1194702144","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194702144?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:20","pubTimestamp":1783945239,"startTime":"0","endTime":"0","summary":"B&K Corporation Limited (B&K) disclosed that patient enrollment for the Phase II clinical trial of its recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel, Pro-101-2, has been...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119055","title":"B&K Completes Phase II Trial Enrollment for Pro-101-2 Diabetic Foot Ulcer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119055","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119055?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:14","pubTimestamp":1783944868,"startTime":"0","endTime":"0","summary":"B&K completes Phase II trial enrollment for Pro-101-2 diabetic foot ulcer treatmentB&K reported full patient enrollment in its Phase II trial of Pro-101-2 for diabetic foot ulcers.No results were pres","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL2d1jPX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102493221","title":"B&K Corp-B Reports Stable Share Capital with 100% Compliance on Public Float in June 2026 Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=1102493221","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102493221?lang=en_us&edition=fundamental","pubTime":"2026-07-03 16:43","pubTimestamp":1783068232,"startTime":"0","endTime":"0","summary":"B&K CORPORATION LIMITED (B&K Corp-B) reported no changes to its share structure during June 2026, according to the company’s monthly return submitted to the Hong Kong Stock Exchange on 03 July 2026....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581864","title":"Companies Like B&K (HKG:2396) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581864","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647581864?lang=en_us&edition=fundamental","pubTime":"2026-06-30 08:41","pubTimestamp":1782780084,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2396/bk-shares/news/companies-like-bk-hkg2396-are-in-a-position-to-invest-in-gro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2396/bk-shares/news/companies-like-bk-hkg2396-are-in-a-position-to-invest-in-gro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645786040","title":"B&K Corp shareholders approve share issue mandate at AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2645786040","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645786040?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:05","pubTimestamp":1782137136,"startTime":"0","endTime":"0","summary":"B&K held its annual general meeting on June 22, 2026.Shareholders adopted the 2025 directors’ report, supervisory committee work report, board work report, annual report, audited financial statements.Ernst & Young was reappointed as auditor; the board was authorized to set its remuneration.A profit distribution plan for 2025 was adopted; amendments were approved to the rules for general meetings, board meetings.Special resolutions passed to grant an issue mandate, approve an H-share repurchase mandate, change the company name, amend the articles, abolish the supervisory committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. B&K Corporation Limited published the original content used to generate this news brief via IIS, the regulator","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL8zTNw2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195082438","title":"B&K Corp Schedules 22 June 2026 AGM; Seeks Name Change, 20% Issuance & 10% Buyback Mandates, No 2025 Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1195082438","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195082438?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:03","pubTimestamp":1780052589,"startTime":"0","endTime":"0","summary":"B&K Corporation Limited (B&K Corp) will hold its 2025 annual general meeting on 22 June 2026 at the Metropark Hotel Yingkun Beijing.  Shareholders on record as of the close of business 22 June 2026...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635739042","title":"B&K Corporation Enrolls Patient in Phase 3a Clinical Trial of Burns Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2635739042","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635739042?lang=en_us&edition=fundamental","pubTime":"2026-05-13 11:21","pubTimestamp":1778642516,"startTime":"0","endTime":"0","summary":"B&K Corporation  said it enrolled the first patient in the phase 3a clinical trial of Pro-101-1 to treat deep second-degree burns, according to a Tuesday filing with the Hong Kong bourse.The biopharmaceutical company shares fell 1% in morning trade Wednesday.Pro-101-1 is one of the core products of the company.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197970022","title":"B&K Corp Begins Phase IIIa Trial of Core Burn-Treatment Candidate Pro-101-1 with First Patient Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=1197970022","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197970022?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:23","pubTimestamp":1778592180,"startTime":"0","endTime":"0","summary":"B&K Corporation Limited (B&K Corp) has enrolled the first patient in its Phase IIIa clinical trial of Pro-101-1, a recombinant human platelet-derived growth factor BB (rhPDGF-BB) gel under...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167182587","title":"B&K CORP-B (02396) Achieves First Patient Enrollment in Phase IIIa Trial for Pro-101-1 in Deep Second-Degree Burn Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1167182587","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167182587?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:20","pubTimestamp":1778592020,"startTime":"0","endTime":"0","summary":"B&K CORP-B (02396) has announced that the Phase IIIa clinical trial for Pro-101-1, a product developed by the company for the treatment of deep second-degree burns, has recently completed enrollment...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021405","title":"B&K enrolls first patient in Phase IIIa Pro-101-1 deep second-degree burns trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634021405?lang=en_us&edition=fundamental","pubTime":"2026-05-12 21:12","pubTimestamp":1778591537,"startTime":"0","endTime":"0","summary":"B&K Corporation flagged first patient enrollment in Phase IIIa trial of Pro-101-1 for deep second-degree burns, marking start of pivotal-stage clinical testing.No results have been presented yet; trial is designed to assess whether rhPDGF-BB gel can improve healing outcomes while maintaining an acceptable safety profile.Study uses randomized, double-blind, placebo-controlled design to generate parameters intended to support planning for a subsequent Phase IIIb trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. B&K Corporation Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 12, 2026, and is solely responsible for the inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6sxltL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139014834","title":"B&K CORP-B Reports Stable Share Structure and Confirms Public Float Compliance for April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1139014834","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139014834?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:23","pubTimestamp":1778059427,"startTime":"0","endTime":"0","summary":"B&K CORPORATION LIMITED (B&K CORP-B) released its monthly return for the period ended 30 April 2026, indicating no changes in registered or issued share capital during the month. Registered Share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631513851","title":"B&K Corporation releases 2025 ESG report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631513851","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631513851?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:19","pubTimestamp":1777461576,"startTime":"0","endTime":"0","summary":"B&K Corporation released its FY2025 ESG report, outlining governance oversight for ESG strategy and climate risk management through a board-led framework.R&D spending totaled RMB 89.4 million, with clinical research progress cited for core product PDGF.Scope 1 greenhouse gas emissions were 4.3 tCO2e, with Scope 2 emissions at 163.6 tCO2e.Total energy consumption reached 321.24 MWh, with purchased electricity at 308.32 MWh.Medical waste totaled 1.81 metric tons, with non-hazardous waste at 3.75 metric tons.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. B&K Corporation Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 29, 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL79fd2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631513861","title":"B&K Corp publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631513861","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631513861?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:16","pubTimestamp":1777461365,"startTime":"0","endTime":"0","summary":"B&K Corporation issued annual report for year ended Dec. 31, 2025, highlighting progress toward commercialization of PDGF-based wound-healing therapies.Core burn candidate Pro-101-1 completed Phase IIb trial for deep second-degree burns; Phase IIIa study in China moved into active preparation, with launch meeting completed in 2026Q1.Diabetic foot ulcer candidate Pro-101-2 continued Phase II trial in China; patient enrollment accelerated, with target to complete recruitment in first half of 2026.Pipeline expansion advanced, with China IND clearance obtained on March 19, 2026 for Pro-101-3 studies in fresh wounds, pressure ulcers, and chronic radiation ulcers.International development planning continued, with U.S. FDA IND submission for Pro-101-1 Phase III targeted for 2026Q1; Japan PMDA consultation planned for 2026Q3.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL35RK5Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174173676","title":"B&K CORP-B年报：营收翻倍至5.22亿元，研发持续投入助推PDGF核心产品临床推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1174173676","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174173676?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:10","pubTimestamp":1777461015,"startTime":"0","endTime":"0","summary":"B&K...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"B&K CORP-B年报：营收翻倍至5.22亿元，研发持续投入助推PDGF核心产品临床推进","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198464268","title":"B&K Corp. Plans Articles Overhaul and Abolition of Supervisory Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=1198464268","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198464268?lang=en_us&edition=fundamental","pubTime":"2026-04-17 21:44","pubTimestamp":1776433452,"startTime":"0","endTime":"0","summary":"B&K Corporation Limited announced a proposal to revise its Articles of Association, chiefly to align with updated PRC company regulations and to strengthen corporate governance. Key changes:   1....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02396"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.huarenshengwu.com/en/","stockEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":0.0383},{"period":"3month","weight":-0.3357},{"period":"6month","weight":-0.5914},{"period":"1year","weight":-0.9005},{"period":"ytd","weight":-0.765}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0507},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.0424},{"period":"1year","weight":0.0188},{"period":"ytd","weight":-0.0074}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"B&K Corp Ltd is a China-based company principally engaged in the research and development of biopharmaceutical products. The Company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The Company primarily focus on the discovery, development and commercialization of therapies for wound healing, currently platelet-derived growth factor (PDGF) drugs. The Company mainly operates its businesses in the domestic market.","exchange":"SEHK","name":"B&K CORP-B","nameEN":"B&K CORP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"B&K CORP-B(02396),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest B&K CORP-B(02396) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"B&K CORP-B,02396,B&K CORP-B股票,B&K CORP-B股票老虎,B&K CORP-B股票老虎国际,B&K CORP-B行情,B&K CORP-B股票行情,B&K CORP-B股价,B&K CORP-B股市,B&K CORP-B股票价格,B&K CORP-B股票交易,B&K CORP-B股票购买,B&K CORP-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"B&K CORP-B(02396),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest B&K CORP-B(02396) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}